Sagimet Biosciences Inc.’s SGMT share price has surged by 6.88%, which has investors questioning if this is right time to sell.

In January 2025, Sagimet delivered an oral presentation at the 9 th Annual MASH-TAG Conference highlighting the ...

Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases ...

The gene interacts with two key enzymes: ACETYL-COENZYME A CARBOXYLASE CARBOXYLTRANSFERASE ALPHA SUBUNIT (α-CT), which is essential for fatty acid biosynthesis, and STARCH SYNTHASE 4 (SS4), which ...

Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic ...

SGMT), clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic TVB-3567 is the Company’s second fatty acid synthase (FASN) inhibitor First-in ...